Related Experiment Video
Updated: Jul 14, 2026

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
Published on: July 17, 2018
LRRC4 Orchestrates AP2A1-Containing Clathrin-Coated Vesicles to Disrupt Mitochondrial Cristae and Restrict
Yang Li1,2, Cheng Huang3, Liangqi Jiang1,2
1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
Mitochondrial dynamics and metabolic homeostasis are pivotal for the aggressive progression of glioblastoma (GBM); however, how membrane-bound organelles modulate mitochondrial remodeling remains unclear. In this study, we identified LRRC4 as a Golgi-anchored tumor suppressor that coordinates a novel vesicle-to-mitochondrial axis to inhibit tumor growth. Using single-sample gene set enrichment analysis (ssGSEA), we established a mitoDynamic score and identified LRRC4 as a key downregulated regulator associated with poor prognosis. Mechanistic analyses combining transmission electron microscopy, Blue Native PAGE, showed that LRRC4 engages AP2A1-containing clathrin-coated vesicles in the Golgi apparatus and redirects them to the inner mitochondrial membrane. This targeted vesicular recruitment disrupted the MICOS complex, suppressing Mic60 expression, resulting in cristae collapse, respiratory chain destabilization, and impaired oxidative phosphorylation. Functional assays and xenograft models have demonstrated that structural and metabolic remodeling triggers excessive mitophagy, depletes cellular metabolic fitness, and suppresses GBM proliferation and invasion. Integrating mitoDynamic scoring with mechanistic and rescue experiments established the LRRC4-AP2A1-Mic60 axis as a validated mitochondrial vulnerability. Collectively, these findings revealed a previously unrecognized Golgi mitochondria crosstalk, demonstrated that clathrin-coated vesicles can act as active modulators of mitochondrial architecture, and suggested that targeting Golgi-derived clathrin-coated vesicle-mediated mitochondrial remodeling is a novel therapeutic strategy for GBM.
Insights
LRRC4, a tumor suppressor, uses vesicles to remodel mitochondria, inhibiting glioblastoma (GBM) growth. This novel Golgi-mitochondria pathway offers a new therapeutic target for GBM.
Area of Science:
- Cell Biology
- Oncology
- Mitochondrial Biology
Background:
- Mitochondrial dynamics and metabolic homeostasis are crucial for glioblastoma (GBM) progression.
- The role of membrane-bound organelles in mitochondrial remodeling in GBM is not well understood.
Purpose of the Study:
- To identify novel regulators of mitochondrial remodeling in GBM.
- To elucidate the mechanism by which LRRC4 suppresses GBM growth.
- To explore the potential of targeting Golgi-mitochondria crosstalk for GBM therapy.
Main Methods:
- Single-sample gene set enrichment analysis (ssGSEA) to establish a mitoDynamic score.
- Transmission electron microscopy and Blue Native PAGE to analyze mitochondrial structure and complexes.
- Functional assays and xenograft models to assess GBM proliferation and invasion.
Main Results:
- LRRC4 was identified as a Golgi-anchored tumor suppressor downregulated in GBM, correlating with poor prognosis.
- LRRC4 redirects AP2A1-containing clathrin-coated vesicles to the inner mitochondrial membrane, disrupting the MICOS complex and Mic60 expression.
- This disruption leads to mitochondrial cristae collapse, impaired oxidative phosphorylation, excessive mitophagy, and suppressed GBM proliferation and invasion.
Conclusions:
- A novel Golgi-mitochondria axis involving LRRC4 and clathrin-coated vesicles regulates mitochondrial architecture.
- Targeting this axis represents a potential therapeutic strategy for GBM by exploiting mitochondrial vulnerabilities.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway